Agarikon Index: Mapping Psychedelic Clinics, Trials, and Law

Agarikon: A Screened Index for Psychedelic Medicine

Agarikon is a rigorously screened, source-cited global index that consolidates data on psychedelic clinics, clinical trials, researchers, legislation, and industry organizations. This resource, published on October 1, 2026 (OpenAlex), addresses the longstanding fragmentation in psychedelic medicine by joining disparate data sources—such as clinic directories, trial registries, legislative databases, and funding disclosures—into a single, auditable reference layer. Agarikon’s transparent methodology and explicit legal-status mapping distinguish it from prior aggregators and directories, providing a high-trust tool for researchers, clinicians, policymakers, and industry analysts.

How Agarikon Works: Methodology and Data Sources

Agarikon’s mechanism centers on rigorous screening and explicit source citation at every data edge. The index covers approximately 2,564 treatment clinics, 282 retreats or legal-access points across dozens of countries, 1,619 registered clinical trials, 1,660 researchers with a 9,757-publication corpus, 173 industry organizations, and 1,532 tracked state legislative bills. Each facility and access point is classified by legal status, with the enabling statute cited where available. Key data sources include ClinicalTrials.gov, CMS Open Payments and Medicare Part B, DEA quotas from the Federal Register, OpenAlex and PubMed for publications, and LegiScan for legislative tracking (licensed CC BY 4.0 with explicit attribution requirements).

The screening pipeline is a defining feature: records are classified for relevance upon ingestion, validated at merge, and quarantined with a documented reason if excluded. Excluded records are retained with their rationale, ensuring every decision is auditable; these are published as EXCLUSION_LOG.md and exclusion_log.csv. This level of methodological transparency is rare in health data aggregation and allows users to trace the provenance and rationale behind every inclusion or exclusion, a critical factor for regulatory and clinical due diligence.

Policy, Clinical, and Research Implications

Agarikon’s comprehensive, source-cited mapping of psychedelic medicine infrastructure has several concrete implications for policy, research, and industry. For policymakers, the index enables rapid assessment of the legal landscape, with jurisdiction-specific legal-status classifications and direct links to enabling statutes. This supports evidence-based legislative drafting and regulatory oversight, especially in rapidly evolving jurisdictions such as Oregon (Measure 109) and Colorado (Proposition 122). For researchers and clinicians, Agarikon offers a validated directory of clinical trial sites, investigators, and published work, facilitating collaboration and minimizing redundant or noncompliant research activity. Industry stakeholders gain a reliable map of clinics, retreats, and supply-chain actors, supporting due diligence, risk assessment, and market entry analysis.

One non-obvious insight is Agarikon’s explicit handling of the legal ambiguity that surrounds many clinics: while retreat and legal-access listings are mapped to specific statutes, ordinary clinics are typically classified under general medical law, with the absence of a psychedelic-specific statute noted as a methodological boundary. This honest edge prevents false precision and helps users understand where regulatory uncertainty persists—a critical consideration for legal counsel and compliance teams.

Risks, Limitations, and Unknowns

Despite its rigor, Agarikon faces several risks and limitations. The clinics dataset is a screened aggregation from public directories and state licensing feeds, rather than independently verified field data. This means that while relevance and legal status are carefully classified, the operational status or quality of individual clinics may not be independently confirmed. Legal-status mapping is robust for retreats and access points with clear statutory backing, but remains less precise for clinics operating under general medical law. Furthermore, the index’s reliance on public and licensed data sources means that coverage may lag behind real-world developments, especially in rapidly changing jurisdictions or where data is not routinely published.

Another critical risk is the potential for regulatory or legal changes to outpace the index’s daily rebuild cycle. For example, a sudden change in state law or a new federal enforcement action could render some classifications temporarily inaccurate. Agarikon’s transparent change log and exclusion records mitigate this risk by enabling users to audit and contextualize data, but users must remain vigilant about the temporal validity of the information, especially when making clinical, legal, or investment decisions.

Looking Forward: Toward a Living, Trustworthy Reference Layer

Agarikon sets a new standard for transparency and methodological rigor in psychedelic medicine data aggregation. Its daily rebuilds, explicit legal-status mapping, and auditable exclusion records provide a living reference layer that can adapt to the field’s evolving regulatory and clinical landscape. As more jurisdictions experiment with psychedelic law reform and as clinical research expands, the demand for high-trust, source-cited data will only increase. Agarikon’s approach—prioritizing provenance, transparency, and methodological honesty—offers a model for other emerging fields where regulatory ambiguity and data fragmentation are persistent challenges.

For those navigating the psychedelic ecosystem—whether as researchers, clinicians, attorneys, policymakers, or industry operators—Agarikon’s index is likely to become an indispensable tool for due diligence, compliance, and strategic planning. Its explicit handling of legal ambiguity and exclusion logic provides a level of clarity and auditability that is rare in health and policy data, positioning it as a cornerstone resource as the field matures.

Byline: Dr. Alex M. Carter, PhD (Science Policy Editor, Psychedelic Research Journal). Reviewed by Dr. Alex M. Carter on 2026-10-02. Research based on direct review of Agarikon’s published methodology, dataset, and exclusion logs at agarikon-index.com/data and primary sources cited therein.